



Dedicated To Life

May 18, 2023

Listing Department  
**BSE LIMITED**  
P J Towers, Dalal Street,  
Mumbai-400 001

**Code: 532321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, C/1, Block G,  
Bandra Kurla Complex,  
Bandra (E),  
Mumbai-400 051

**Code: ZYDUSLIFE**

Sub: **Half yearly disclosure of related party transactions**

Ref: **Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations")**

Pursuant to the provisions of regulation 23(9) of the Listing Regulations, please find enclosed the details of Related Party Transactions for the half year ended on March 31, 2023, in the prescribed format.

Please find the same in order.

Yours faithfully,  
For, **ZYDUS LIFESCIENCES LIMITED**

**DHAVAL N. SONI**  
**COMPANY SECRETARY**

Encl.: As above

**Zydus Lifesciences Limited** (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878













































**Zydus Lifesciences Limited [Formerly Known as Cadila Healthcare Limited]**

Disclosure of related party transactions for the half year/ six months ended March 31, 2023

Amount in INR Million except stated otherwise

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments				Details of loans/ investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost	Tenure	Nature [Loans/ Investments ]	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
306	Nesher Pharmaceuticals (USA) LLC	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.		39	-									
307	Hercon Pharmaceuticals LLC	Zydus Noveltech Inc.	Subsidiary Company	Loan		-	N.A.	39	-	-					Loan	6 M SOFR + 50 bps	1 Year	Unsecured	Business Purpose
308	Hercon Pharmaceuticals LLC	Zydus Noveltech Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.		299	335									
309	Zydus Healthcare (USA) LLC	Zydus Worldwide DMCC	Subsidiary Company	Sale of goods or services		-	N.A.	10	-	-									
310	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Sale of goods or services		-	N.A.	18	-	-									
311	Zydus Healthcare (USA) LLC	Zydus Therapeutics INC	Subsidiary Company	Sale of goods or services		-	N.A.	3	-	-									
312	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.	5	-	-									
313	Zydus Healthcare (USA) LLC	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.	5	-	-									
314	Zydus Healthcare (USA) LLC	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.	7	-	-									
315	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Payables - Loans	-	N.A.		203	206									
316	Zydus Healthcare (USA) LLC	Zydus Pharmaceuticals (USA) Inc.	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.		1	-									
317	Zydus Healthcare (USA) LLC	Zydus Therapeutics INC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.		3	1									
318	Zydus Healthcare (USA) LLC	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.		3	0									
319	ZyVet Animal Health Inc	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.	210	-	-									
320	ZyVet Animal Health Inc	Zydus Animal Health and Investments Limited	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.		10	52									
321	Zydus International Private Limited	Zydus Netherlands B.V.	Subsidiary Company	Interest received		-	N.A.	4	-	-									
322	Zydus International Private Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Interest received		-	N.A.	3	-	-									
323	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Interest received		-	N.A.	4	-	-									
324	Zydus International Private Limited	Laboratorios Combix S.L.	Subsidiary Company	Interest received		-	N.A.	3	-	-									
325	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Interest received		-	N.A.	351	-	-									
326	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Loan		-	N.A.	209	-	-					Loan	6 M EURIBOR+ 75 BPS	3 Year	Unsecured	Business Purpose

**Zydus Lifesciences Limited [Formerly Known as Cadila Healthcare Limited]**  
Disclosure of related party transactions for the half year/ six months ended March 31, 2023

Amount in INR Million except stated otherwise

										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.								
S. No.	Details of the party entering into the transaction	Details of the counterparty		Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financials indebtedness is incurred to make or give loans/ investments				Details of loans/ investments			
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness [Loans/ issuance of debt/ any other]	Details of other indebtedness	Cost	Tenure	Nature [Loans/ Investments]	Interest Rate (%)	Tenure	Secured/ Unsecured
327	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Loan		-	N.A.	306	-	-								
328	Zydus International Private Limited	Zydus Netherlands B.V.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.		196	223								
329	Zydus International Private Limited	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.		293	330								
330	Zydus International Private Limited	Zydus France, SAS	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.		90	327								
331	Zydus International Private Limited	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.		266	300								
332	Zydus International Private Limited	Zydus Worldwide DMCC	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.		15,798	16,034								
333	Zydus France, SAS	Laboratorios Combix S.L.	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.	1	-	-								
334	Zydus Healthcare S.A. (Pty) Ltd	Simayla Pharmaceuticals (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Loans	-	N.A.		406	418								
335	Zydus Healthcare S.A. (Pty) Ltd	Simayla Pharmaceuticals (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.		49	51								
336	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Sale of goods or services		-	N.A.	0	-	-								
337	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Reimbursement of Expenses Recovered	-	N.A.	238	-	-								
338	Script Management Services (Pty) Ltd	Zydus Healthcare S.A. (Pty) Ltd	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.		2	0								
339	Zydus Pharmaceuticals Mexico Services Company SA De C.V.	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Sale of goods or services		-	N.A.	0	-	-								
340	Zydus Pharmaceuticals Mexico Services Company SA De C.V.	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Outstanding Payables - Other than loans	-	N.A.		9	-								
341	Zydus Pharmaceuticals Mexico Services Company SA De C.V.	Zydus Pharmaceuticals Mexico SA De CV	Subsidiary Company	Any other transaction	Outstanding Receivables - Other than loans	-	N.A.		-	0								

**Notes:**

- Amount mentioned as 0 denotes value less than INR 1 Million.
- Opening and closing balance are not given where there was no transaction of Investment during the half year ended March 31, 2023.
- Receivables / Payables other than loans represents combined balance against sales / purchase pertaining to goods/ propoerty, plant and equipment / various services / reimbursement of expenses. Hence shown separately.
- Loans given and repaid within reporting period is not disclosed.